SPAGO NANOMEDICAL AB

Interim report

January- September 2024

Progress for the Tumorad program

JULY – SEPTEMBER IN BRIEF

- Net sales for the quarter amounted to KSEK 485 (KSEK 271)
- The loss for the quarter amounted to KSEK –8,763 (KSEK -7,755)
- Operating expenses for the quarter amounted to KSEK -10,650 (KSEK -8,795)
- Earnings per share, before and after dilution, for the quarter amounted to SEK -0.03 (SEK -0.09)

JANUARY – SEPTEMBER IN BRIEF

- Net sales for the year amounted to KSEK 1,294 (KSEK 472)
- The loss for the year amounted to KSEK –24,679 (KSEK -32,806)
- Operating expenses for the year amounted to KSEK -30,403 (KSEK -36,945)
- Earnings per share, before and after dilution, for the year amounted to SEK -0.09 (SEK -0.36)
- Cash and cash equivalents at the end of the quarter amounted to KSEK 39,946 (KSEK 25,974)

SIGNIFICANT EVENTS DURING THE QUARTER

- The independent Data Monitoring Committee (DMC) recommended to proceed the clinical phase I/IIa study Tumorad-01 with the candidate drug ^{177}Lu-SN201 according to plan. The recommendation is based on an analysis of data from the first three treated patients in the study that the DMC considers shows a satisfactory safety profile. The study proceeds according to plan with recruitment of patients at the two hospitals activated so far.

SIGNIFICANT EVENTS AFTER THE QUARTER

- The Board decided that all available resources will be focused on the development of Tumorad with the company's primary priority being the execution of the ongoing clinical study Tumorad-01. To ensure that crucial clinical milestones can be reached and to position the company well for the future, organizational changes have been made. As part of our strategic focus on the Tumorad program, any continued clinical development within SpagoPix will take place in collaboration with a partner, through out-licensing or commercial partnership, or be financed by grants.

SPAGO NANOMEDICAL IN BRIEF

Spago Nanomedical AB (publ) is a Swedish clinical phase company, developing products for treatment and imaging diagnostics of cancer and other severe diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO).

The company intends to develop pharmaceuticals and imaging diagnostic products for diseases with a high medical need under its own auspices until clinical proof-of-concept. Subsequent development and future commercialization are intended to take place through strategic license or partnership agreements with established pharmaceutical companies with the necessary capacity and global reach in each project area.

The company's operations are based on a patented material for the design of functional nanoparticles that accumulate physiologically in tumors, thus enabling higher precision in image diagnostics and treatment of cancer and other severe diseases. With the development programs Tumorad and SpagoPix, Spago Nanomedical aims to improve the conditions for effective healthcare for large groups of patients while meeting the need for stronger positioning and renewal of product portfolios of commercial pharmaceutical companies.

*The **Tumorad®** development program aims to develop new pharmaceuticals for radionuclide therapy against aggressive cancer. Preclinical results show that the candidate drug in the program, ^{177}Lu-SN201, accumulates in tumors, delays growth and prolongs survival at clinical useful doses. This opens up for wide use of ^{177}Lu-SN201 for the treatment of various cancers where there are currently no opportunities for clinically effective treatment with radiopharmaceuticals, such as ovarian cancer and triple-negative breast cancer. A phase I/IIa clinical study in patients with advanced cancer is ongoing to evaluate safety, tolerability, biodistribution and initial efficacy of ^{177}Lu-SN20. See further under "Program - Tumorad".*

*The **SpagoPix** development program aims to improve the precision of MRI scans for suspected endometriosis and cancer by launching a selective contrast agent for more precise visualization of tumors and other lesions. Initial clinical results show that the product candidate within the program, pegfosimer manganese (formerly SN132D), provides clinically relevant contrast in breast cancer tumors, in the liver and in the pancreas, while maintaining good safety. Selective contrast enhancement has also been observed in endometriosis lesions in a clinical phase IIa clinical study. Active business development work continues to find potential partners or other solutions for continued clinical development. See further under "Program - SpagoPix".*



CEO STATEMENT

The third quarter of 2024 has been an important period for Spago Nanomedical where we have taken crucial steps forward in the clinical development of our prioritized Tumorad program with the candidate drug ^{177}Lu-SN201. The single most important event during the quarter was that the independent Data Monitoring Committee (DMC) gave us a positive recommendation to continue the phase I/IIa study Tumorad-01 according to plan. The Committee's decision was based on data from the first three treated patients who demonstrated a satisfactory safety profile in the study with no serious adverse events reported. This is an important step in the continued development of ^{177}Lu-SN201 and strengthens our confidence in the candidate drug as a potentially promising treatment for cancer.

To ensure that crucial clinical milestones can be reached and enable faster progress, we have conducted a strategic review and decided that all available resources will be focused on the Tumorad program and the ongoing phase I/IIa study. As part of this positioning, we have decided that all internal preclinical discovery will be terminated. This gives us the financial space to generate results from the study's phase I part with existing funds and advancing the study towards phase IIa. We are convinced that this is the right way to better structure the company for current and future phases and to create long-term shareholder value**.**

Our goal is that the next cohort of patients in the Tumorad-01 study is ready for evaluation by DMC in the beginning of next year. The results from this patient cohort, which is expected to include patients with different tumor types, will provide us with additional valuable data on safety and biodistribution. The data is crucial for decisions on the phase IIa part of the study and determining which group or groups of patients we should proceed with to generate the first efficacy results. We continue to work intensively to meet all of the study's objectives and get closer to results that can support continued clinical development of ^{177}Lu-SN201.

The interest in the radionuclide therapies continues to be high in the industry and several of the major global pharmaceutical companies are making significant investments in the field. We are also noticing the increasing interest and our candidate drug, ^{177}Lu-SN201, has the potential to meet a major medical need in several cancer indications. As the clinical development progresses, we increase the pace of business development and have, among other things, met and had several fruitful discussions with potential partners at the partnering conferences Bio Japan and BIO Europe during the autumn. We are confident about the opportunities to strengthen our position in this growing field.

In parallel, active business development work continues to find potential partners for the SpagoPix development program. The product candidate pegfosimer manganese has shown in clinical studies that our technology platform for the selective accumulation of nanoparticles in solid tumors via the EPR effect works and thereby provides support for Tumorad as a treatment concept. As part of our strategic focus on the Tumorad program, any continued clinical development within SpagoPix will take place in collaboration with a partner, through out-licensing, commercial partnership, or be financed by grants. With favorable clinical data in both breast cancer and endometriosis, together with a growing interest in women's health in the industry, we are optimistic about the possibilities of moving the program forward in some form.

In summary, we have strengthened the foundation for our continued development during this quarter. By focusing our resources on Tumorad-01 but at the same time continuing to explore commercial opportunities for the SpagoPix program, we are working purposefully towards creating both medical and financial success. We are well equipped to take on the challenges ahead and look forward to continuing the development of our programs.

Mats Hansen, CEO Spago Nanomedical AB

PROGRAM - TUMORAD

BACKGROUND

Radiation therapy has long been used effectively in the fight against cancer. Along with surgery and chemotherapy, radiotherapy is a cornerstone in the treatment of several cancers. The development and approvals of new generations of radioactive drugs for internal radiotherapy, known as radionuclide therapy (RNT), has led to a renaissance in the field. Radionuclide therapy has received increased attention in recent years, in line with clinical and commercial advances and a number of major deals completed in the field. In Tumorad, nanoparticles for physiological accumulation in tumors are loaded with clinically effective radioactive isotopes, which can open for effective internal radiation therapy of aggressive and spread cancer with high precision. Tumorad may therefore provide the opportunity to treat cancer that cannot be treated with other types of radioactive drugs.

Despite important advances and new therapies, long-term survival is however still unsatisfactory in many cases, especially in the treatment of spread (metastatic) cancer. Treatment resistance is a significant challenge in cancer care, and there is therefore a clear clinical need for new treatment options. Radioactive treatment is effective against cancer and has long been an established cornerstone in the treatment of many forms of cancer. Unlike the radionuclide therapies that are currently used clinically and which target specific cancers, Tumorad is designed for physiological and selective accumulation in tumors and other lesions via the well documented "Enhanced Permeability and Retention (EPR) effect"[1]. The mechanism of action gives Tumorad the opportunity to treat different types of solid tumors and can thus be considered to have a significant market value.

MARKET

Interest in RNT is very high and is shown not least by several of deals in recent years where large pharmaceutical companies have acquired or invested billions in RNT projects. Today there are just over a handful of approved RNT products and the market is expected to grow rapidly in steps with further market approvals, increased subsides, and a remaining large medical need. Tumorad is expected to be used both as a complement to surgery, chemotherapy, and immunotherapies, as well as first treatment options. This opens up opportunities for optimized development and for broad use in the market. Based on mortality data in a number of major cancer indications (colorectal, gastric, breast, pancreatic, and ovarian cancer) which based on clinical science can be expected to be candidates for treatment with ^{177}Lu-SN201 (indications with documented EPR effect), as well as prices of comparable existing pharmaceuticals, the company estimates the annual addressable market for Tumorad to billions.

STATUS

As the core of the Tumorad particles is based on the same platform as the nanoparticles used for SpagoPix, there are significant synergies between the programs with regards to the material's structure and production. SpagoPix has shown in the clinical studies SPAGOPIX-01 and SPAGOPIX-02 that the material is safe to give to patients and that the mechanism for selective accumulation of the nanoparticles in tumors via the EPR effect works. Furthermore, the radioactive isotope ^{177}Lu is already used clinically today and has been shown to have an effect in the treatment of cancer.

Extensive non-clinical development and optimization work has previously resulted in the candidate drug, ^{177}Lu-SN201 with the desired exposure to radioactivity in tumors, while minimizing the impact on other organs. During the second quarter, the company reported favorable results from a study with ^{177}Lu-SN201 as monotherapy in a model for triple-negative breast cancer, a very aggressive and difficult-to-treat form of cancer in which the tumor cells often have resistance to chemotherapy even before chemotherapy treatment begins and which represents approximately 15 percent of all breast cancer cases. The results show a better tumor-inhibiting effect compared to drugs used in standard treatment, in parallel with a low level of radiotoxicity. The findings support continued non-clinical development to explore ^{177}Lu-SN201 as monotherapy and in combination therapy in triple-negative breast cancer, The company has also shown that ^{177}Lu-SN201 reduces tumor growth and prolongs survival by 37 percent in a preclinical model for colorectal cancer (Mattisson et al., 2023). The material has shown a good safety profile in regulatory preclinical toxicology studies, as well as favorable distribution in the body (biodistribution) in preclinical studies.

Production of SN201 on a larger scale for clinical studies is completed and a clinical phase I/IIa dose escalation and dose expansion, first-in-human study in patients with advanced cancer is ongoing. The primary objective of the study is to evaluate safety, biodistribution, tolerability and initial efficacy of ^{177}Lu-SN201. In the Phase I part of the study, the first patient group consisting of three patients has been successfully treated with at least one dose of ^{177}Lu-SN201. Further, the independent DMC recommended the study to continue according to plan. No serious adverse events (SAEs) had been

[2] Eriksson et al., 2014 & Mattisson et al., 2023

reported and the DMC considered the safety to be satisfactory in this patient group. The study is initially being conducted at a number of clinics in Australia and as the study progresses, clinics in other countries may also be included.

PROGRAM - SPAGOPIX

BACKGROUND

SpagoPix is a selective contrast agent with extraordinary signal strength and potential to significantly improve the precision of magnetic resonance imaging (MRI). Through more precise visualization of lesions such as endometriosis and soft tissue, the chances of successful treatment of patients are increased.

The product candidate within SpagoPix, pegfosimer manganese, is as well as the candidate drug ^{177}Lu-SN201 (Tumorad) designed for physiological and selective accumulation in tumors and other lesions via the EPR effect. Furthermore, the contrast agent has a significantly better ability to amplify the signal measured in MRI examinations (relaxivity) compared to current contrast agents.

The combination of the selective mechanism of action and the high signal strength gives MRI images better contrast between diseased and healthy tissue, which creates the conditions for more optimally utilizing the potential of MRI. Pegfosimer manganese can provide the ability to detect endometriosis and tumors with higher precision than is possible with today's contrast agents, thereby opening for improved imaging diagnostics, more efficient surgery, screening of high-risk patients, monitoring and follow-up of patients before and after surgery, and facilitating automated image analysis for example with AI-based systems. Improved methods for accurate visualization and diagnosis of endometriosis and tumors would increase the probability of a successful treatment and thus the patients' chance of better quality of life and survival. Pegfosimer manganese is also free of gadolinium, which means that, in addition to better precision, the risk of negative side effects due to the use of this foreign substance has also been eliminated. Instead of gadolinium, pegfosim manganese contains manganese (Mn) to enhance the signal detected during an MRI examination. Manganese is an essential element that occurs in many of our most common foods and is needed to maintain good health. In summary, these properties make pegfosimer manganese a unique contrast agent with the potential to significantly improve the imaging of endometriosis and tumors compared to conventional MRI contrast agents.

MARKET

It is estimated that more than 190 million women of reproductive age worldwide are affected by endometriosis, and endometriosis accounts for as high social healthcare costs as type 2 diabetes or rheumatoid arthritis. Endometriosis takes an average of 9 years to diagnose and the clinical need for improved diagnostic methods, especially non-invasive, is large.

Cancer is today one of the most common causes of illness and death among adults, especially the elderly. An early and correct cancer diagnosis is in many cases decisive for a positive treatment result. Survival is very dependent on early diagnosis because the chances of successful treatment decrease if the cancer has spread.

Already today, MRI constitutes clinical practice with several different areas of application, and a gadolinium-free contrast agent with higher precision can both take market shares from existing preparations and increase use even further. A tissue-selective product, free of gadolinium, is expected to be priced higher than today's products. This means that the possible market size is very attractive.

STATUS

Results from the clinical phase I study SPAGOPIX-01 in patients with confirmed breast cancer, show that pegfosimer manganese provides positive contrast in MRI images of human breast cancer tumors while maintaining a good safety profile. In addition to the positive contrast in breast cancer tumors, all MRI images in the study show that SN132D also generates good contrast in the pancreas and liver. Beyond confirming that pegfosimer manganese can improve the diagnosis and monitoring of suspected and diagnosed breast cancer with MRI, the results also confirm the ability of the company's unique platform material to accumulate selectively and without background noise in solid human tumors. This can be seen as a clinical validation of the platform technology and allows for the use of the company's nanomaterial also for therapeutic purposes. The results from the study were presented at the 2022 San Antonio Breast Cancer Symposium and further publications based on the final study report are planned.

At the end of 2023, the company announced positive top line data from the clinical phase IIa study SPAGOPIX-02, which included patients with endometriosis. The analysis of MRI-images from SPAGOPIX-02 shows that the primary endpoint of measuring the MRI enhancing effect in endometriotic lesions that was identified by the treating gynecologist was met. Contrast enhancement with pegfosimer manganese was observed in the majority of lesions confirmed by unenhanced

ultrasound. In addition, pegfosimer manganese shows a good safety profile in patients with endometriosis. Exploratory analysis is suggestive of enhancement in active inflammatory lesions but not of indolent fibrotic lesions, supporting the clinical relevance of pegfosimer manganese-enhanced MRI, which may be of great importance for disease staging and treatment planning. Final results will be published later in one or several appropriate scientific journals and at scientific conferences.

In the next stage, SN132D will be tested in larger clinical studies and/or in different indications prior to market approval. As part of our strategic focus on the Tumorad program, any continued clinical development within SpagoPix will take place in collaboration with a partner, through out-licensing, commercial partnership, or be financed by grants. Based on this, active business development work continues to find potential collaboration partners.

FINANCIAL DEVELOPMENT

RESULTS

Operating expenses amounted to KSEK -10,650 (KSEK -8,795) for the quarter and KSEK -30,403 (KSEK -36,945) for the year. The higher operating costs during the beginning of last year were primarily related to the production of material to the ongoing clinical phase I/IIa study Tumorad-01.

Total revenue amounted to KSEK 1,554 (KSEK 845) for the quarter and KSEK 4,800 (KSEK 3,458) for the year. The increase compared to the previous year relates mainly to the increased innovation support from the Australian authorities for the development activities that the company carried out during the quarter in Australia.

The operating result amounted to KSEK -9,096 (KSEK -7,950) for the quarter and KSEK -25,603 (KSEK 33,487) for the year. Earnings per share before and after dilution amounted to SEK -0.03 (SEK -0.09) for the quarter and SEK -0.09 (SEK -0.36) for the year.

INVESTMENTS AND FINANCIAL POSITION

At the end of the quarter, cash and cash equivalents amounted to KSEK 39,946 (KSEK 25,974).

Cash flow from operating activities amounted to KSEK -7,626 (KSEK -5,197) for the quarter and KSEK -27,263 (KSEK -35,806) for the year. The higher negative cash flow during last year mainly relates to the production of material to the ongoing clinical phase I/IIa study Tumorad-01. Cash flow from investment activities amounted to KSEK -56 (KSEK -0) for the quarter and KSEK -174 (KSEK -102) for the year. Cash flow from financing activities amounted to KSEK -71 (KSEK -221) for the quarter and KSEK 22,166 (KSEK -221) for the year. The cash flow refers to the net proceeds received during the quarter from the exercise of warrants series TO12. In total, approximately 97% of the warrants were exercised for subscription of 123,480,752 new shares

At the end of the quarter, the company's equity amounted to KSEK 41,122 (KSEK 24,330) and the equity ratio to 87.3 percent (81.1 percent). Equity per share, before dilution, amounted to SEK 0.12 (SEK 0.27).

SHARES AND SHARE CAPITAL

The number of registered shares as of September 30, 2024 amounted to 348,196,206. Spago Nanomedical's share is traded on the Nasdaq First North Growth Market, with the ticker SPAGO. During the third quarter, the Swedish Companies Registration Office implemented the annual general meeting's decision on reduction of the share capital, whereby the quota value is changed to SEK 0.01 and the share capital to SEK 3,481,962.06. The number of shareholders at the end of the period were 2,718. The largest owners at the end of the period were Peter Lindell, with companies and related parties, Mikael Lönn, Avanza Pension, Eva Redhe and Tiel Ridderstad.

The company has, per year-end 2023, changed accounting principle from capitalization model to costing model regarding expenses from to development projects related to the design and testing of new or improved products. For further information, see note 1.

CONSOLIDATED INCOME STATEMENT

Amounts in KSEK	Note	Jul-Sep 2024	Jul-Sep 2023	Jan-Sep 2024	Jan-Sep 2023	Jan-Dec 2023
Income						
Net sales		485	271	1 294	472	1 203
Other operating income		1 069	574	3 506	2 986	4 728
Total income	1	**1 554**	**845**	**4 800**	**3 458**	**5 931**
Operating costs						
Project costs		-4 371	-3 136	-11 097	-18 256	-24 486
Other external costs		-2 166	-1 762	-6 764	-6 221	-7 958
Personnel costs		-3 969	-3 387	-12 080	-11 786	-15 711
Depreciation/amortization of fixed assets		-78	-70	-236	-205	-281
Other operating costs		-68	-441	-225	-476	-568
Total operating costs		**-10 650**	**-8 795**	**-30 403**	**-36 945**	**-49 005**
OPERATING RESULT		**-9 096**	**-7 950**	**-25 603**	**-33 487**	**-43 073**
Financial items						
Interest income and similar items		333	195	924	681	850
Total financial items		**333**	**195**	**924**	**681**	**850**
RESULT AFTER FINANCIAL ITEMS		**-8 763**	**-7 755**	**-24 679**	**-32 806**	**-42 223**
PROFIT/LOSS FOR THE PERIOD		**-8 763**	**-7 755**	**-24 679**	**-32 806**	**-42 223**

CONSOLIDATED BALANCE SHEET

Amounts in KSEK	Note	30 Sep 2024	30 Sep 2023	31 dec 2023
ASSETS				
NON-CURRENT ASSETS	1			
Tangible assets				
Equipment, tools, fixtures and fittings		691	747	925
Financial assets				
Other long-term receivables		325	96	153
Total non-current assets		**1 016**	**843**	**1 078**
CURRENT ASSETS				
Accounts receivables		201	0	370
Other current assets		505	615	990
Prepaid expenses and accrued income		5 437	2 568	5 331
Cash and cash equivalents		39 946	25 974	45 217
Total current assets		**46 089**	**29 157**	**51 907**
TOTAL ASSETS		**47 105**	**30 000**	**52 985**
EQUITY AND LIABILITIES				
Equity				
Equity	1	41 122	24 330	41 317
Total eqiuty		**41 122**	**24 330**	**41 317**
Provisions				
Provisions for pensions		325	96	153
Other provision		80	23	38
Total provisions		**405**	**119**	**191**
Current liabilities				
Accounts payables		3 045	2 826	6 391
Other current liabilities		435	462	448
Accrued expenses and deferred income		2 099	2 263	4 638
Total current liabilities		**5 578**	**5 551**	**11 477**
TOTAL EQUITY AND LIABILITIES		**47 105**	**30 000**	**52 985**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Amounts in KSEK	Share capital	Not reg. capital	Dev. fund	Other contributed capital	Translation difference	Other equity incl. profit/loss	Total equity
Opening balance Jan 1, 2023	**90 944**	**0**	**88 113**	**257 146**	**0**	**-239 047**	**197 156**
Change of accounting principle			-88 113			-51 744	**-139 857**
Adjusted opening balance Jan 1, 2023	**90 944**	**0**	**0**	**257 146**	**0**	**-290 790**	**57 299**
Translation difference					31		**58**
Reduction of share capital	-81 849					81 849	**0**
Issuance costs				-221			**-221**
Profit/loss						-7 755	**-32 806**
Closing balance Sep 30, 2023	**9 094**	**0**	**0**	**256 925**	**31**	**-216 696**	**24 330**
Share issue	9 765	3 091		17 999			**30 855**
Issuance costs				-4 364			**-4 364**
Translation difference					-60		**-87**
Profit/loss						-9 417	**-9 417**
Closing balance Dec 31, 2023	**18 859**	**3 091**	**0**	**270 559**	**-29**	**-251 164**	**41 317**
Opening balance, Jan 1, 2024	**18 859**	**3 091**	**0**	**270 559**	**-29**	**-251 164**	**41 317**
Registration of share capital	3 091	-3 091					**0**
Share issue	12 869			13 077			**25 946**
Issuance costs				-1 519			**-1 519**
Reduction of share capital	-31 338					31 338	**0**
Translation difference					57		**57**
Profit/loss						-24 679	**-24 679**
Utgående balans 30 Sep 2024	**3 482**	**0**	**0**	**282 117**	**27**	**-244 505**	**41 122**

CONSOLIDATED CASHFLOW STATEMENT IN SUMMARY

Amounts in KSEK	Jul-Sep 2024	Jul-Sep 2023	Jan-Sep 2024	Jan-Sep 2023	Jan-Dec 2023
Cash flow from operating activities and before changes in working capital	**-8 614**	**-7 844**	**-24 229**	**-33 245**	**-41 751**
Changes in working capital	988	2 647	-3 034	-2 561	-3 158
Cash flow from operating activities	**-7 626**	**-5 197**	**-27 263**	**-35 806**	**-44 909**
Cash flow from investing activities	-56	0	-174	-101	-506
Cash flow from financing activities	-71	-221	22 166	-221	28 530
Cash flow for the period	**-7 754**	**-5 418**	**-5 271**	**-36 127**	**-16 884**
Cash and cash equivalents at the beginning of the period	47 700	31 392	45 217	62 101	62 101
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	**39 946**	**25 974**	**39 946**	**25 974**	**45 217**

DATA PER SHARE

	Jul-Sep 2024	Jul-Sep 2023	Jan-Sep 2024	Jan-Sep 2023	Jan-Dec 2023
Earnings per share, before and after dilution, SEK	-0.03	-0.09	-0.09	-0.36	-0.43
Equity per share, before dilution, SEK	0.12	0.27	0.12	0.27	0.19
Average number of shares before dilution	348 196 206	90 943 723	277 630 211	90 943 723	97 978 083
Average number of shares after dilution	348 196 206	90 943 723	349 918 812	90 943 723	104 954 588
Number of shares at the end of the period	348 196 206	90 943 723	348 196 206	90 943 723	219 507 121

OTHER KEY FIGURES

	Jul-Sep 2024	Jul-Sep 2023	Jan-Sep 2024	Jan-Sep 2023	Jan-Dec 2023
Average number of employees	13	12	12	13	13
Equity ratio, %	87.3	81.1	87.3	81.1	78.0

FINANCIAL DEFINITIONS

EQUITY RATIO
Equity in relation to total balance sheet

EQUITY PER SHARE, BEFORE DILUTION
Equity in relation to the number of shares at the end of the period

EARNINGS PER SHARE, BEFORE DILUTION
Result for the period in relation to the average number of shares

EARNINGS PER SHARE, AFTER DILUTION
Result for the period in relation to the average number of shares increased by the number added at full dilution. In accordance with IAS 33, no dilution effect arises in cases where a conversion entails a lower loss per share.

ACCOUNTING PRINCIPLES

Spago Nanomedical AB (publ) reports in accordance with the Swedish Annual Accounts Act and the Swedish Accounting Standards Board's general advice BFNAR2012:1 Annual Report and consolidated statements (K3). The company's accounting principles are described in Note 1 in the company's annual report for 2023.

Unless otherwise stated, this Interim report refers to the Group. Figures in parentheses refer to the corresponding period last year. The amounts are expressed in KSEK, which in this report refers to thousands of Swedish kronor.

NOTE 1

The company has, per year-end 2023, changed accounting principle from capitalization model to costing model regarding expenses from to development projects related to the design and testing of new or improved products. The change was made to adapt the company's accounting principles to industry practice and was made with retroactive application, i.e. recalculation of comparative figures from previous financial years is done as if the new accounting principle had always been applied.

EFFECTS IN THE INCOME STATEMENT	Jul-Sep 2023			Jan-Sep 2023		
Amounts in KSEK	w/o change of accounting principle	Adjustment	with change of accounting principle	w/o change of accounting principle	Adjustment	with change of accounting principle
Income	1 487	-642	845	6 876	-3 418	3 458
PROFIT/LOSS FOR THE PERIOD	**-7 113**	**-642**	**-7 755**	**-29 387**	**-3 418**	**-32 806**

EFFECTS IN THE BALANCE SHEET	30 Sep 2023		
Amounts in KSEK	w/o change of accounting principle	Adjustment	with change of accounting principle
Intangible assets	143 275	-143 275	0
TOTAL ASSETS	**173 275**	**-143 275**	**30 000**
EQUITY	167 606	-143 275	24 330
TOTAL EQUITY AND LIABILITIES	**173 275**	**-143 275**	**30 000**

SIGNIFICANT RISKS AND UNCERTAINTIES

Spago Nanomedical's operations are exposed to a number of risk factors and elements of uncertainty, both operational and financial. Risk and uncertainty factors mainly consist of risks related to research and development, clinical trials, patents and other rights, collaborations and commercialization of projects, and financing. A detailed account of the company's significant financial risks is described on pages 24-25 in the annual report for 2023.

TRANSACTIONS WITH RELATED PARTIES

Chairman of the board, Hans Arwidsson, has during the year provided consulting services to the company within business development. Transactions with related parties have been made according to agreement based on market terms.

INVESTOR RELATIONS

This report can be downloaded from the website www.spagonanomedical.se or ordered from the company by e-mail or mail: Spago Nano Medical AB, Scheelevägen 22, 223 63 Lund, Sweden. For further information, please contact CEO Mats Hansen on 046 811 88 or e-mail mats.hansen@spagonanomedical.se.

OTHER

This report has not been reviewed by the company's auditors. This is a translation of the Swedish interim report.

CERTIFICATION

The board and the CEO ensure that the interim report provides a fair overview of the company's operation, financial position and results and describes significant risks and uncertainties to which the company is exposed.

Lund November 6, 2024

Spago Nanomedical AB (publ)
Org.no: 556574-5048

Hans Arwidsson
Chairman of the board

Kari Grønås

Alan Raffensperger

Nicklas Westerholm

Mats Hansen
CEO